Search & Analyze

Gland Pharma Ltd.

HealthcarePharmaceuticals & Drugs

www.glandpharma.com BSE: 543245NSE: GLAND

₹2,972.00BSE0.46%

07 Sep, 4:01 PM

₹2,972.00

₹49.06K Cr

43.46

4.62

10.56%

₹3,041.95

₹2,920.00

₹3,041.95

₹1,575.00

Customise metrics bar

Price Performance

Peer Comparison

Name
SUN PHARMA. SUNPHARMA	1,899.80	37.69	4,55,825.66	0.84	2,901.23	26.53%	15,299.88	10.46%	19.11
DIVI'S LAB. DIVISLAB	9,305.00	84.45	2,47,018.51	0.32	902.00	65.50%	3,080.00	27.80%	21.51
TORRENT PHAR TORNTPHARM	4,913.00	85.68	1,86,874.73	0.77	566.00	3.28%	4,921.00	54.85%	19.27
ZYDUSLIFE ZYDUSLIFE	1,155.00	25.53	1,15,211.69	0.09	990.20	-34.90%	8,017.00	21.96%	21.39
CIPLA LTD. CIPLA	1,395.95	33.46	1,12,773.00	0.93	785.55	-39.18%	7,119.28	2.33%	16.00
LAURUSLABS LAURUSLABS	1,868.25	92.32	1,00,943.83	0.11	362.07	123.94%	2,026.31	29.10%	18.20
LUPIN LTD. LUPIN	2,105.00	17.41	96,254.46	0.86	1,416.98	16.01%	8,276.89	32.04%	28.86
Gland Pharma Ltd. GLAND	2,972.00	43.46	49,061.91	0.67	316.96	47.09%	1,800.27	19.57%	14.96

Quarterly Results

consolidated figures in ₹ Crores · Quarterly

Particulars	Mar 2024	Jun 2024	Sep 2024	Dec 2024	Mar 2025	Jun 2025	Sep 2025	Dec 2025	Mar 2026	Jun 2026
	1,537.45	1,401.71	1,405.83	1,384.05	1,424.91	1,505.62	1,486.88	1,695.36	1,742.79	1,800.27
Expenses	1,178.80	1,137.31	1,108.78	1,024.10	1,077.39	1,137.86	1,172.99	1,260.49	1,229.77	1,310.90
	358.65	264.40	297.06	359.95	347.52	367.76	313.89	434.88	513.02	489.37
	23.33%	18.86%	21.13%	26.01%	24.39%	24.43%	21.11%	25.65%	29.44%	27.18%
	42.15	51.43	59.66	58.49	44.03	57.53	84.16	38.83	111.47	61.23
Interest	9.96	5.62	6.11	22.82	7.45	11.50	7.82	3.93	10.03	4.36
	92.61	91.96	93.83	96.33	95.76	101.05	106.31	107.65	108.66	111.26
	298.23	218.24	256.78	299.30	288.33	312.74	283.92	362.13	505.80	434.98
	35.48%	34.13%	36.31%	31.61%	35.30%	31.10%	35.30%	27.79%	27.51%	27.13%
	192.42	143.76	163.53	204.69	186.54	215.48	183.68	261.48	366.68	316.96
	11.68	8.73	9.93	12.42	11.32	13.08	11.15	15.87	22.26	19.21

Profit & Loss

consolidated figures in ₹ Crores · Annual

Particulars	FY 2021-22 (Mar)	FY 2022-23 (Mar)	FY 2023-24 (Mar)	FY 2024-25 (Mar)	FY 2025-26 (Mar)
No of Months	12.00	12.00	12.00	12.00	12.00
INCOME :
	4,400.71	3,624.60	5,664.72	5,616.50	6,430.65
	4,400.71	3,624.60	5,664.72	5,616.50	6,430.65
EXPENDITURE :
Increase/Decrease in Stock	36.69	-46.92	127.88	103.41	-3.42
Raw Material Consumed	2,072.53	1,732.34	2,045.20	1,986.97	2,246.35
Power & Fuel Cost	95.05	124.84	229.99	199.15	202.85
Employee Cost	338.57	403.26	1,256.89	1,401.56	1,628.84
Other Manufacturing Expenses	179.85	194.23	327.19	347.18	407.61
General and Administration Expenses	94.28	120.53	217.36	206.62	211.87
Selling and Distribution Expenses	40.98	27.03	37.46	27.48	29.76
Miscellaneous Expenses	32.61	44.53	89.66	75.20	77.25
	2,890.56	2,599.84	4,331.65	4,347.58	4,801.11
Operating Profit (Excl OI)	1,510.15	1,024.76	1,333.07	1,268.92	1,629.54
	223.94	240.46	170.24	213.61	316.33
	1,734.09	1,265.23	1,503.31	1,482.53	1,945.87
Interest	5.24	7.45	26.20	42.00	33.28
PBDT	1,728.85	1,257.78	1,477.11	1,440.53	1,912.59
	110.30	146.74	344.57	377.87	423.67
Profit Before Taxation & Exceptional Items	1,618.55	1,111.04	1,132.54	1,062.66	1,488.93
Exceptional Income / Expenses		-56.46			-24.35
	1,618.55	1,054.58	1,132.54	1,062.66	1,464.58
Provision for Tax	406.89	273.54	360.08	364.13	437.26
	1,211.66	781.04	772.46	698.53	1,027.32
Extra items			0.00	0.00	0.00
Consolidated Net Profit	1,211.66	781.04	772.46	698.53	1,027.32
Profit Balance B/F	4,022.68	5,234.35	6,015.39	6,787.85	7,156.87
Appropriations	5,234.35	6,015.39	6,787.85	7,486.37	8,184.19
Equity Dividend %			2,000.00%	1,800.00%	2,000.00%
	73.75	47.42	46.90	42.40	62.35
Adjusted EPS	73.75	47.42	46.90	42.40	62.35

Balance Sheet

consolidated figures in ₹ Crores

Particulars	FY 2021-22 (Mar)	FY 2022-23 (Mar)	FY 2023-24 (Mar)	FY 2024-25 (Mar)	FY 2025-26 (Mar)
	16.43	16.47	16.47	16.48	16.48
Share Warrants & Outstandings	13.24	1.67	1.38	0.05	45.52
Total Reserves	7,127.95	7,940.59	8,705.99	9,134.21	10,295.95
Reserve excluding Revaluation Reserve	7,127.95	7,940.59	8,705.99	9,134.21	10,295.95
	7,157.62	7,958.72	8,723.84	9,150.74	10,357.95
Unsecured Loans	3.82	3.26	106.54	77.66	69.93
Deferred Tax Assets / Liabilities	87.76	84.20	169.69	162.74	152.06
Other Long Term Liabilities	2.39	2.22	75.17	70.87	64.55
Long Term Provisions			137.21	145.99	195.64
Total Non-Current Liabilities	93.98	89.68	488.60	457.27	482.17
Trade Payables	462.85	587.35	767.75	820.41	833.87
Other Current Liabilities	76.42	109.48	520.07	619.87	657.53
Short Term Provisions	42.75	32.30	110.54	124.56	117.00
Total Current Liabilities	582.03	729.13	1,398.36	1,564.85	1,608.40
Total Liabilities	7,833.62	8,777.54	10,610.81	11,172.85	12,448.52
Gross Block	2,081.32	2,294.96	5,011.68	5,613.37	6,784.55
Less: Accumulated Depreciation	579.13	724.41	1,064.93	1,466.14	2,292.22
Net Block	1,502.19	1,570.55	3,946.75	4,147.24	4,492.33
Capital Work in Progress	180.75	177.22	237.88	150.56	342.18
Long Term Loans & Advances	286.40	128.96	119.43	87.69	83.07
Other Non Current Assets	2.21		661.59	4.43	4.16
Total Non-Current Assets	1,981.54	1,876.73	4,965.66	4,389.91	4,921.74
Currents Investments	154.87
Inventories	1,185.67	1,945.30	1,655.24	1,685.22	1,743.89
Sundry Debtors	1,074.81	871.39	1,558.69	1,516.53	1,891.38
Cash and Bank	3,093.44	3,770.68	1,839.43	2,556.21	3,359.11
Other Current Assets	96.75	91.00	102.61	149.85	128.41
Short Term Loans and Advances	246.55	222.44	489.19	875.13	404.00
Total Current Assets	5,852.08	6,900.81	5,645.15	6,782.94	7,526.79
Net Current Assets (Including Current Investments)	5,270.05	6,171.68	4,246.79	5,218.09	5,918.38
Total Assets	7,833.62	8,777.54	10,610.81	11,172.85	12,448.52
Contingent Liabilities	12.76	22.07	15.58	21.38	10.12
Total Debt	3.93	3.82	319.78	269.21	243.36
	434.84	483.12	529.56	555.40	625.91
Adjusted Book Value	434.84	483.12	529.56	555.40	625.91

Cash Flow

consolidated figures in ₹ Crores

Particulars	FY 2021-22 (Mar)	FY 2022-23 (Mar)	FY 2023-24 (Mar)	FY 2024-25 (Mar)	FY 2025-26 (Mar)
No of Months	12.00	12.00	12.00	12.00	12.00
	1,618.55	1,054.58	1,132.54	1,062.66	1,464.58
Adjustment	-28.27	38.19	223.60	211.94	276.76
Changes In working Capital	-393.01	-417.94	-53.20	-6.06	-254.50
Cash Flow after changes in Working Capital	1,197.28	674.83	1,302.95	1,268.53	1,486.84
Cash Flow from Operating Activities	790.77	363.97	996.80	914.73	1,031.39
Cash Flow from Investing Activities	-1,002.62	1,208.19	-1,756.91	1,704.74	137.73
Cash Flow from Financing Activitie	34.90	14.92	-799.42	-433.48	-416.97
Net Cash Inflow / Outflow	-176.95	1,587.08	-1,559.53	2,185.99	752.14
Opening Cash & Cash Equivalents	492.46	318.82	1,908.90	357.09	2,556.21
Effect of Foreign Exchange Fluctuations	3.31	3.00	7.72	13.13	50.75
Closing Cash & Cash Equivalent	318.82	1,908.90	357.09	2,556.21	3,359.11

Ratios

Valuation

43.46

4.62

22.18

7.30

68.43

644.34

Profitability

10.56

14.96

8.70

25.34

15.98

Leverage & Liquidity

0.02

4.68

45.01

Returns

0.67

0.54

Shareholding Pattern

Numbers in percentages

Particulars	Jun '24	Sep '24	Dec '24	Mar '25	Jun '25	Sep '25	Dec '25	Mar '26	Jun '26
	51.83	51.83	51.83	51.83	51.83	51.83	51.83	51.83	51.77
	39.71	39.84	39.84	40.17	40.25	40.55	40.56	40.65	39.18
	8.45	8.32	8.33	7.99	7.93	7.63	7.61	7.52	9.05
	48.17	48.17	48.17	48.17	48.17	48.17	48.17	48.17	48.23
No. of Shareholders	1,22,665	1,22,358	1,21,075	1,13,788	1,10,671	97,151	94,578	91,500	1,08,266

Corporate Actions

Showing: All

Date	Type	Details	Ex-Date	Record Date
2026-07-24	Board Meeting	Quarterly Results
2026-05-15	AGM
2026-05-15	Ex Dividend	Rs.20.0000 per share(2000%)Final Dividend	2026-08-11	2026-08-11

Insider Trading

Date	Person	Category	Transaction Type	Shares
2026-06-04	Jayatheerth Advani	Market	Sell	1,000
2026-05-28	K RAGHURAMACHANDRA RAO	Market	Sell	1,000
2026-05-28	K RAGHURAMACHANDRA RAO	Market	Sell	1,000
2026-05-25	SREENIVASA RAO SURAGAM	Market	Sell	500
2026-05-25	Jayatheerth Advani	Market	Sell	500

Sector Overview

HealthcarePharmaceuticals & Drugs

Gland Pharma Ltd. operates in the Healthcare sector under the Pharmaceuticals & Drugs industry. This sector is one of the key drivers of the Indian economy and is closely tracked by the relevant Nifty sectoral index.

Company Profile

Corporate information and contact details

Key Management

10 members across the board and senior leadership

Sampath Kumar Pallerlamudi

Company Secretary & Compliance Officer

—

Srinivas Sadu

Chairman

₹17.81 Cr

Mar '26

Naina Lal Kidwai

Non Executive Independent Director

₹1.07 Cr

Mar '26

Udo Jahannes Vetter

Non Executive Independent Director

₹39.00 L

Mar '26

Essaji Goolam Vahanvati

Non Executive Independent Director

₹37.00 L

Mar '26

Wenjie Zhang

Non Independent & Non Executive Director

—

Allen Zhang

Non Independent & Non Executive Director

—

Wei Huang

Non Independent & Non Executive Director

—

William Robert Keller

Non Executive Independent Director

—

Jia Ai (Allen) Zhang

Non Independent & Non Executive Director

—

GLAND Latest News

News

10 of 10 articles

COMPANY2 Sept 2026 · 12:26

USFDA completes routine GMP inspection at Gland Pharma’s Visakhapatnam facility

The inspection was concluded with ZERO Form 483 Observations

EQUITY14 Aug 2026 · 09:39

Gland Pharma informs about appointment of chief executive officer

EQUITY11 Aug 2026 · 12:26

Gland Pharma zooms on reporting 47% jump in Q1 consolidated net profit

The total consolidated income of the company has increased by 19.09% at Rs 1,861.50 crore for Q1FY27

COMPANY11 Aug 2026 · 12:00

Gland Pharma reports 47% jump in Q1 consolidated net profit

The total consolidated income of the company has increased by 19.09% at Rs 1,861.50 crore for Q1FY27

EQUITY10 Aug 2026 · 09:26

Gland Pharma soars on executing strategic agreement with Global Pharmaceutical Company

The agreement is for the technology transfer, manufacturing and supply of a portfolio of sterile injectable products for global markets

COMPANY10 Aug 2026 · 09:08

Gland Pharma executes strategic agreement with Global Pharmaceutical Company

The agreement is for the technology transfer, manufacturing and supply of a portfolio of sterile injectable products for global markets

EQUITY6 Aug 2026 · 10:50

Gland Pharma gains on partnering with Neuland Laboratories

The company will establish a sterile manufacturing suite for APIs pertaining to microparticle depot products

COMPANY6 Aug 2026 · 10:10

Gland Pharma, Neuland Laboratories join forces for sterile API manufacturing

The company will establish a sterile manufacturing suite for APIs pertaining to microparticle depot products

EQUITY29 Jul 2026 · 12:53

Gland Pharma trades higher on getting USFDA’s approval for Sugammadex Injection

According to IQVIA, the product had US sales of approximately $1.6 billion for the twelve months ending April 2026

COMPANY29 Jul 2026 · 12:44

Gland Pharma gets USFDA’s approval for Sugammadex Injection

According to IQVIA, the product had US sales of approximately $1.6 billion for the twelve months ending April 2026

GLAND

₹2,972.00

+0.46%